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Abstract
Papillomaviruses have been liked to several skin disorders in the dog. In order to have a suitable
diagnostic tool for canine papillomavirus detection, eight PCRs with published primer combinations
were evaluated. The most sensitive PCR was used to demonstrate that papillomavirus DNA can be
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Papillomaviruses have been liked to several skin disorders in the dog. In order to have a 21 
suitable diagnostic tool for canine papillomavirus detection, eight PCRs with published 22 
primer combinations were evaluated. The most sensitive PCR was used to demonstrate that 23 





Papillomaviruses (PVs) are predominantly species-specific pathogens of humans and animals 25 
that can induce benign as well as malignant neoplasias in the skin and mucous membranes 26 
(24). PV DNA has also been detected on the skin of clinically healthy humans and certain 27 
animal species (1-4, 6, 7, 16, 17). Likewise, clinically healthy dogs have been shown to carry 28 
antibodies against PVs (14). Nevertheless, previous attempts to detect PV DNA on the skin of 29 
healthy dogs have been unsuccessful (3). 30 
To address this issue, eight PCR assays with previously published primer combinations 31 
targeting either the L1 or the E1 open reading frame were assessed (Table 1 and references 32 
therein). These PCR assays were evaluated for their ability to detect the DNA of the seven 33 
classified canine PVs (CPVs) (5, 9, 12, 20-22). Furthermore, the sensitivity and specificity of 34 
each assay was determined in the same context. 35 
Eight different published primarily broad range primer pairs were tested (Table 1). Three of 36 
them are targeting conserved regions in the L1 open reading frame (ORF), namely 37 
canPVf/FAP64, FAP59/FAP64 and AR-L1F1/AR-L1R3 while five of the primer pairs target 38 
conserved stretches in the E1 ORF, namely CP4/CP5, PPF1/CP5, PapF/PapR, AR-E1F1/AR-39 
E1R2, and AR-E1F2/AR-E1R9. Primers amplifying 585 bp of canine GAPDH were designed 40 
to test for host DNA dogGAPDH f (GGT GAT GCT GGT GCT GAG TA) and dogGAPDH r 41 
(GAC CAC CTG GTC CTC AGT GT). RedTaq (Sigma, Buchs, Switzerland) ready reaction 42 
mix was used according to the manufacturer’s recommendations. Three different protocols 43 
were used. In case of the primer combinations canPVf/FAP6410, AR-L1F1/AR-L1R3, AR-44 
E1F1/AR-E1R2 and  AR-E1F2/AR-R9 10 min of initial denaturation at 94°C were followed 45 
by 45 cycles of 1 min at 94°C, 1 min at 50°C and 1 min at 72°C. The program concluded with 46 
a final elongation step of 72°C for 10 min. In case of FAP59/FAP64 and dogGAPDH 47 
f/dogGAPDH the protocol used started with 3 min at 94°C followed by 45 cycles of 30 sec at 48 





CP4/CP5, PPF1/CP5 and PapF/PapR started as well with 3 min at 94°C but was then 50 
followed by 40 cycles of 30 sec at 94°C, 30 sec at 42°C and 30 sec at 72°C. 51 
To visualize PCR results 1% Agarose gels containing Ethidium bromide were used. Images 52 
were taken after a run of 35 minutes in an electric field of 5 V cm-1 in TAE buffer.  53 
Rolling circle amplification (RCA) was used to test for circular potentially papillomaviral 54 
DNA (Rector et al. 2004). DNA (1 µl) was used for RCA in a TempliPhi Amplification kit 55 
(General Electrics Biosciences, Glattbrugg, Switzerland). The protocol supplied by the 56 
manufacturer was used, with slight modifications. Namely, 1µl of 10 mM dNTPs were added 57 
and the reaction time was prolonged to 16 h at 30 °C. Two templates were used alternatively 58 
for the evaluation, one complete genomic clone of CPV1 in a pBluescript II KS+ vector 59 
(Stratagene, La Jolla, CA, USA) and one pET-DEST42 vector (Invitrogen, Basel, 60 
Switzerland) containing the entire L1 coding sequence of CPV1. The amplified DNA was 61 
digested with the restriction endonuclease EcoRI or EcoRV respectively. To visualize results 62 
1% Agarose gels containing Ethidium bromide were used. Images were taken after 90 63 
minutes in an electric field of 5 V cm-1 in TAE buffer. 64 
To evaluate the spectrum of the primers, clones or PCR products of the target regions from 65 
the seven PVs were used as templates. Whole genomes cloned into pBluescript II KS+ 66 
(Stratagene, La Jolla, CA, USA) were used in case of CPV1 (EcoRI), CPV3 (SacI), CPV5 67 
(ClaI), CPV6 (EagI) and CPV7 (HinDIII), a partial genomic clone was used in case of CPV4 68 
(KpnI). PCR products of E1 or L1 target regions were used in case of CPV2 and CPV4 (E1 69 
CPV2 forward GTG GTT TGT TGT GCA TGA GG, E1 CPV2 reverse CCA AAG TCC 70 
ATG GTT CAT CC, L1 CPV2 forward TGA TAC ACA GGA AGC GCA AA, L1 CPV2 71 
reverse TGC CTT CCT TCT TTT CTT TGA, E1 CPV4 forward ACC CAG GAG AGG GTA 72 
CCA GT, E1 CPV4 reverse CCC TCG TCC TCT TGA TCA CT). For the evaluation of the 73 
dogGAPDH primers, a PCR product of the whole-dogGAPDH (forward ATG GTG AAG 74 





determine the approximate detection levels of the PCRs serial dilutions were made from 109 76 
down to 101 molecules of every template. For that purpose DNA concentrations of the 77 
template stock solutions were measured using a Spectrophotometer (ND-1000, Thermo 78 
Scientific, Zurich, Switzerland). According to the size of the individual templates the amount 79 
of molecules per microliter was calculated. DNA from a keratinocyte cell culture (Bex) being 80 
free of any known PV DNA served as negative control for PV primers (Figure S2). Therefore 81 
DNA was extracted from 106 cells with a DNeasy extraction kit (Qiagen, Hombrechtikon, 82 
Switzerland) resulting in 83 ng/µl. Eight serial dilutions 1:10 were made.  83 
The test population of 95 dogs was recruited from patients of the small animal hospital of the 84 
University of Zurich displaying no clinical signs of any described kind of papillomatosis. To 85 
obtain skin samples from these dogs, fresh cytobrush sticks were used in the oral cavity and 86 
on the interdigital skin. The cytobrushes were rubbed six turns on the target regions and 87 
afterwards placed in an 1.5ml Eppendorf tube containing 1ml of sterile 0.9% NaCl. The 88 
samples were kept at 4°C for no longer than 24 hours and were then stored below -18°C until 89 
extraction. Before DNA extraction, each cytobrush was flushed repeatedly with the 0.9% 90 
NaCl it had been kept in. To concentrate all cells and cell debris at the bottom of the tube, 91 
tubes (still containing the cytobrush tip) were centrifuge at 15000 g for 10 min. The cytobrush 92 
tip and the 0.9% NaCl were then carefully removed except for about the last 25 µl. DNA was 93 
afterwards extracted using the DNeasy extraction kit (Qiagen, Hombrechtikon, Switzerland) 94 
following the manufacturer’s instructions, eluting DNA finally in 100µl sterile water. 95 
Extraction and handling of this sample DNA was performed entirely separated from any other 96 
PV research. 97 
All sampling was carried out with respect to the Swiss regulations about research on animals. 98 
As shown in Table 1, PCR with the L1 primer combination canPVf/FAP64 detected five of 99 
the seven CPVs at a target concentration of 102 molecules or less, while CPV2- and CPV7-100 





CP4/CP5 performed similarly but needed more target to detect CPV3. All tested PCRs with 102 
other primer combinations showed less sensitivity and/or less specificity (Table 1, S1). The 103 
reason may be that some primers aligned well with certain CPV sequences but poorly with 104 
others (S2). RCA is a frequently used alternative method to amplify PV DNA (18). 105 
Evaluation of its sensitivity revealed that it required a minimum of 106 molecules to 106 
successfully amplify PV DNA (data not shown), thus RCA was not favoured for the detection 107 
of CPV DNA on the healthy skin.  108 
Based on the primer evaluation, the canPVf/FAP64 PCR was chosen to assess cytobrush 109 
samples from the skin and oral mucosa of 95 asymptomatic dogs. A dogGAPDH PCR assay 110 
(requiring 104 molecules for a positive detection) was used as an amplification control. This 111 
PCR provided a positive signal with all samples taken from the oral cavity and with 81% of 112 
samples taken from the interdigital skin (S3). CPV DNA was detected in more than 50% of 113 
the dogs (S3), i.e. in 23% of oral samples whose complementary skin samples were negative; 114 
14% of skin samples (oral samples negative); 15% of samples from both locations. In 48% of 115 
the dogs PV DNA was detected neither in skin nor in oral samples. Interestingly, in two cases 116 
putative PV DNA was amplified from the skin with canPVf/FAP64 although the dogGAPDH 117 
PCR assay had been negative. A number of randomly selected products arising from 118 
canPVf/FAP64-mediated PCR were sequenced. The sequences obtained from two oral and 119 
three skin samples were clearly identified as CPV1. In contrast, the amplification products of 120 
five oral and two skin samples did not yield meaningful sequencing results, most probably 121 
due to the presence of DNA from more than one PV type in the sample. 122 
In conclusion, the sensitivity and specificity for each of eight previously described PV primer 123 
pairs was assessed in the context of PCR for the detection of CPV DNA. Application of a 124 
broad-range, high sensitive primer pair suggests that the clinically unaffected skin and oral 125 
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Table 1: Primers and detection levels indicating the minimum of molecules required for 205 
detection. Nomenclature for nucleotide symbols according to Cornish-Bowden (8). 206 
 207 
 
CPV1 CPV2 CPV3 CPV4 CPV5 CPV6 CPV7 
canPVf / FAP64 (13) 

















FAP59 / FAP64 (10) 

















AR-L1F1 / AR-L1R3 (19) 

















CP4 / CP5 (11) 

















PPF1 / CP5 (11) 

















PapF / PapR (23) 

















AR-E1F1 / AR-E1R2 (19) 

















AR-E1F2 / AR-E1R9 (15) 
E1 primer combination 
ATGGTNCAGTGGGCNTATGA / 
CATTWGTDGTDAYMAGSAKRGGVGGGCA 
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